It has been suggested that altered interleukin (IL) regulation may be involved in the pathogenesis of schizophrenia. In this cross-sectional, case-controlled study, patients with schizophrenia and a control group of healthy subjects, matched by age, sex and body mass index, were evaluated. The levels of IL-1a and IL-2 in blood serum were measured by enzyme-linked immunosorbent assay. The fasting serum IL-2 levels were significantly higher in patients with schizophrenia compared with the control subjects, but there was no difference between the fasting serum levels of IL-1a in patients with schizophrenia and the control subjects. Our results suggest that patients with schizophrenia have altered IL-2, but not IL-1a, regulation.
Introduction
Several immunological abnormalities are associated with schizophrenia, but currently their significance is largely unknown. 1 -8 There is some evidence that the pathophysiology of schizophrenia is related to activation of the inflammatory response system, as indicated by increased serum concentrations of interleukin (IL) 6, IL-6 receptor, IL-1 receptor antagonist and IL-2 receptor, and lower serum concentrations of CC16, an endogenous anti-inflammatory protein with immunosuppressive and antiinflammatory effects. 9, 10 Immunological alterations, such as cellular changes and deviating cytokine production, may play a role in pathogenesis of schizophrenia, 11 -16 but the data are variable and often contradictory. 17 It has been postulated that autoimmune processes may influence the pathogenesis of symptoms in some schizophrenic patients, and the finding of altered IL regulation has been regarded as additional proof that schizophrenia has an autoimmunological background. 18 We therefore investigated the relationship between ILs and psychopathology in schizophrenia.
Patients and methods

PATIENTS
The study investigated 36 male schizophrenic patients and 20 male healthy controls, matched for age and body mass index.
Patients with chronic inflammatory diseases and those who used medication that may alter IL regulation (e.g. anti-psychotic drugs, anti-inflammatory drugs and steroids) were excluded. All patients underwent routine investigations for accompanying metabolic, hepatic and renal diseases. No patient had In the schizophrenic group, the activity of the psychiatric disease was stable for at least 3 months prior to the start of the study, and any medication used to treat schizophrenia was withdrawn 1 month prior to the start of the study. The diagnosis of schizophrenia was based on the criteria given in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 19 All subjects provided written consent to participate in the study, which was approved by the Institutional Review Board.
BIOCHEMICAL MEASUREMENTS
The patients were required to fast, and blood samples were collected via an intravenous catheter in venepuncture tubes coated with ethylenediaminetetra-acetate. The blood was promptly centrifuged, separated and stored at -70 ºC until the IL assays were performed. IL-1α and IL-2 levels were determined by enzymelinked immunosorbent assay (Enzyme Immunoassay kit, Immunotech, Marseille, France). The inter-and intra-assay coefficients of variation for the IL-1α and IL-2 levels were 4.4% and 6.0%, and 2.4% and 3.0%, respectively.
STATISTICAL ANALYSIS
All data are presented as mean ± SD. The Mann-Whitney U-test was used to compare the two groups, and P-values of < 0.05 were considered statistically significant.
Results
The serum IL-2 levels were significantly higher in patients with schizophrenia than the control subjects (313.6 ± 390.2 pg/ml versus 48.3 ± 46.8 pg/ml, P < 0.001). However, there was no significant difference between the serum IL-1α levels in patients with schizophrenia (29.1 ± 60.9 pg/ml) and the control subjects (12.9 ± 2.4 pg/ml). The results are summarized in Table 1 .
Discussion
Growing evidence suggests that, in addition to providing communication between immune cells, specific cytokines play a role in signalling to the brain to produce neurochemical, neuroendocrine, neuroimmune and behavioural changes. This signalling may be part of a generalized, comprehensive mechanism to mobilize resources in the face of physical and/or psychological stress, and to maintain homeostasis. The clinical implications of these findings are far-reaching and include a possible role for cytokines in the pathophysiology of specific psychiatric disorders, such as major depression and schizophrenia, and Alzheimer's disease. The effects of cytokines in the central nervous system may provide a possible mechanism for the 'sickness behaviour' of patients with severe 
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infection or cancer, as well as for the neuropsychiatric adverse effects of treatment with interferons and ILs. 20 The pathophysiology of psychotic and other symptoms in schizophrenia remains a mystery, despite decades of research. Even though it has been suspected for many years that autoimmune mechanisms may play a role in the pathophysiology of schizophrenia, firm evidence for this hypothesis is lacking. 21 The ILs play an important role in the development and maintenance of the immune system, 22 and previous studies support the hypothesis of an autoimmune dysfunction in some schizophrenic patients. 17 Sirota et al. 22 reported that IL-1 was significantly increased in schizophrenic patients in comparison with controls. Licinio et al. 23 found that the levels of IL-2, but not IL-1α, in the cerebrospinal fluid were higher in neuroleptic-free schizophrenic patients than in healthy subjects matched for sex and age. Because IL-2 increases dopaminergic neurotransmission and participates in autoimmunity and cell growth, the authors postulated that elevated levels of central IL-2 might contribute to the increased dopaminergic neurotransmission, autoimmune phenomena and abnormal brain morphology described in some patients with schizophrenia.
Kim et al. 24 reported that the plasma levels of IL-2 were significantly higher in schizophrenic patients in relation to controls. They also found a significant correlation between changes in IL-2 and the Scale for the Assessment of Positive Symptoms (SAPS). They concluded that the cytokines may modulate schizophrenic symptomatology in schizophrenia. McAllister et al. 14 concluded that the levels of IL-2, a molecule that has both neurodevelopmental and neuroregulatory roles, may be a factor in relapse in schizophrenia.
In this study, schizophrenic patients were found to have significantly higher levels of IL-2 in relation to the control group. There was much more variability in the IL levels in the schizophrenic patients than in the normal controls, and this was believed to be related to varying levels of disease activity. Schizophrenic patients had different features (e.g. disease duration, medication and social status) that may affect disease activity and symptomatology. Nonetheless, these observations suggest that ILs may have an important role in the pathogenesis and activation of schizophrenia.
These findings support the hypothesis that immune activation is involved in the pathophysiology of schizophrenia. The autoimmune basis for schizophrenia has been investigated for the past 60 years, but further studies will still be required to determine a possible link between cytokines and the pathophysiology of psychotic symptoms in schizophrenia. A better understanding of the role of cytokines in various brain activities will enhance knowledge of specific psychobiological mechanisms in health and disease, and provide opportunities for novel treatment interventions. 
